beta

ALKS

Alkermes plc

Alks

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Alkermes PLC is a fully integrated, biopharmaceutical company. It applies its scientific expertise and proprietary technologies to research, develop and commercialize pharmaceutical products to address unmet medical needs of patients.

Market Cap: 9.2 Billion

Primary Exchange: Nasdaq Global Select

Website: http://www.alkermes.com

Shares Outstanding: 154 Million

Float: 152 Million

Dividend: 0.0 (0.0%)

Beta: 1.986142

Sector: Healthcare

Industry: Biotechnology

Short Interest (Jan 12, 2018): 11.6 Million

Ethical Flags

Animal testing

Longest drawdown: 1472 trading days

From: 2015-12-28 To: 2019-10-18

Lowest Point:

Alkermes Advances ALKS 4230 into Monotherapy Expansion Phase of ARTISTRY-1 in Patients With Renal Cell Carcinoma or Melanoma

via: PR Newswire at 2019-06-12 03:00:00:000

-- Initiation of Monotherapy Efficacy Evaluation Follows Selection of Recommended Phase 2 Dose in Dose-Escalation Stage -- -- Proof-of-Mechanism Demonstrated by Desired Expansion of Tumor-Killing Immune Cells While Avoiding Activation of Immunosuppressive Cells -- DUBLIN , June 12… read more...

Alkermes Advances ALKS 4230 into Monotherapy Expansion Phase of ARTISTRY-1 in Patients With Renal Cell Carcinoma or Melanoma

via: PR Newswire at 2019-06-12 03:00:00:000

-- Initiation of Monotherapy Efficacy Evaluation Follows Selection of Recommended Phase 2 Dose in Dose-Escalation Stage -- -- Proof-of-Mechanism Demonstrated by Desired Expansion of Tumor-Killing Immune Cells While Avoiding Activation of Immunosuppressive Cells -- DUBLIN , June 12… read more...

FDA Ad Com tomorrow on utility of higher-dose opioids

via: SeekingAlpha at 2019-06-10 13:06:51:000

The FDA's Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee will jointly mee t tomorrow and Wednesday, June 11 & 12, to seek public input on the clinical utility and safety concerns associated with higher range opioid an… read more...

FDA Ad Com tomorrow on utility of higher-dose opioids

via: SeekingAlpha at 2019-06-10 13:06:51:000

The FDA's Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee will jointly mee t tomorrow and Wednesday, June 11 & 12, to seek public input on the clinical utility and safety concerns associated with higher range opioid an… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud